Literature DB >> 34646107

Direct Primary Care: A Successful Financial Model for the Clinical Practice of Lifestyle Medicine.

Amy R Mechley.   

Abstract

Primary care has been shown to significantly decrease the overall cost of a population's health care while improving the quality of each person's well-being. Lifestyle medicine (LM) is ideally positioned to be delivered via primary care and has been shown to improve short- and long-term health outcomes of patients and populations. Direct primary care (DPC) represents a viable alternative to the fee-for-service reimbursement model. It has been shown to be economically and financially sustainable. Furthermore, it has the potential to fulfill the Quadruple Aim of health care in the United States. LM practiced in a DPC model has the potential to transform health care delivery. This article will discuss the need for health care systems change, provide an overview of the DPC model, demonstrate a basic understanding of the benefits, and review the steps needed to de-risk the investment of time, money, and resources for our future DPC providers.
© 2021 The Author(s).

Entities:  

Keywords:  chronic disease management; direct primary care; lifestyle medicine; population health; primary care

Year:  2021        PMID: 34646107      PMCID: PMC8504342          DOI: 10.1177/15598276211006624

Source DB:  PubMed          Journal:  Am J Lifestyle Med        ISSN: 1559-8276


  3 in total

1.  Lifestyle medicine: treating the causes of disease.

Authors:  Mark A Hyman; Dean Ornish; Michael Roizen
Journal:  Altern Ther Health Med       Date:  2009 Nov-Dec       Impact factor: 1.305

2.  From triple to quadruple aim: care of the patient requires care of the provider.

Authors:  Thomas Bodenheimer; Christine Sinsky
Journal:  Ann Fam Med       Date:  2014 Nov-Dec       Impact factor: 5.166

3.  Health Care Industry Insights: Why the Use of Preventive Services Is Still Low.

Authors:  Susan Levine; Erin Malone; Akaki Lekiachvili; Peter Briss
Journal:  Prev Chronic Dis       Date:  2019-03-14       Impact factor: 2.830

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.